前列腺癌根治性前列腺切除术后持续性前列腺特异性抗原与死亡风险
这项队列研究纳入1992至2020年在2个学术中心接受根治性前列腺切除术的T1N0M0至T3N0M0前列腺癌患者,评估术后持续性PSA与死亡风险的关系。研究发现术前PSA>20 ng/mL与≤20 ng/mL患者中持续性PSA对死亡风险存在显著交互作用,且持续性PSA水平升高与更差预后相关。结论认为术后至少评估3个月PSA可能减少过度治疗。
要点
- 术前PSA>20 ng/mL的持续性PSA患者较≤20 ng/mL者全因死亡风险aHR 0.69、前列腺癌特异性死亡风险aHR 0.41。
- 持续性PSA水平升高与全因死亡风险aHR 1.14和前列腺癌特异性死亡风险aHR 1.27相关。
- 术后至少评估3个月PSA可能减少过度治疗,术前PSA>20 ng/mL者术后放疗联合ADT或ADT使用更频繁且中位时间更短。
核心结论
- 根治性前列腺切除术后至少评估3个月PSA可能减少过度治疗,本研究中较高的持续性PSA水平与更差预后相关。
研究设计与样本
- 队列研究,纳入1992至2020年在2个学术中心接受根治性前列腺切除术的T1N0M0至T3N0M0前列腺癌患者,发现队列30461例,验证队列12837例。
- 评估术前PSA>20 ng/mL与≤20 ng/mL和术后持续性PSA与不可测PSA对前列腺癌特异性死亡风险及全因死亡风险的交互作用,并调整已知前列腺癌预后因素、手术年龄、手术年份及术后放疗和雄激素剥夺治疗的时间依赖性使用。
- 随访数据收集至2023年11月,数据分析时间为2024年7月至2025年1月。
主要发现
- 发现队列中位(IQR)年龄64(59-68)岁,验证队列中位(IQR)年龄59(54-64)岁。
- 与不可测PSA患者相比,持续性PSA患者中术前PSA>20 ng/mL较≤20 ng/mL与全因死亡风险降低相关(aHR 0.69;95%CI 0.51-0.91;P=.01;交互作用P<.001)。
- 与不可测PSA患者相比,持续性PSA患者中术前PSA>20 ng/mL较≤20 ng/mL与前列腺癌特异性死亡风险降低相关(aHR 0.41;95%CI 0.25-0.66;P<.001;交互作用P=.02)。
- 持续性PSA水平升高与全因死亡风险升高相关(aHR 1.14;95%CI 1.04-1.24;P=.004),与前列腺癌特异性死亡风险升高相关(aHR 1.27;95%CI 1.12-1.45;P<.001)。
- 术前PSA>20 ng/mL者术后放疗联合ADT或ADT使用更频繁且中位时间更短(446例中244例[54.7%],中位[IQR]2.68[1.51-4.40]个月) vs 术前PSA≤20 ng/mL者(972例中338例[34.8%],中位[IQR]3.30[2.00-5.39]个月)。
临床怎么用
- 作者认为,根治性前列腺切除术后至少评估3个月PSA可能减少过度治疗。
- 本研究中心的做法是:对于术前PSA>20 ng/mL患者,术后放疗联合ADT或ADT使用更频繁且中位时间更短(54.7% vs 34.8%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Whether the conventional 1.5-month to 2.0-month time interval following radical prostatectomy (RP) for prostate cancer (PC) is sufficient to accurately document a persistent prostate-specific antigen (PSA) remains unanswered. OBJECTIVE: To evaluate the time necessary to accurately document a persistent PSA level after RP. DESIGN, SETTING, AND PARTICIPANTS: This cohort study evaluated whether a significant interaction existed between (1) a pre-RP PSA level greater than 20 ng/mL vs 20 ng/mL or less and (2) persistent PSA vs undetectable PSA after RP on PC-specific mortality (PCSM) risk and all-cause mortality (ACM) risk, adjusting for known PC prognostic factors, age at RP, year of RP, and the time-dependent use of post-RP radiation therapy (RT) and androgen deprivation therapy (ADT). Whether an increasing persistent PSA level was associated with a worse prognosis was also investigated. Patients with T1N0M0 to T3N0M0 PC treated with RP between 1992 and 2020 at 2 academic centers were included. Follow-up data were collected until November 2023. Data were analyzed from July 2024 to January 2025. EXPOSURE: RP. MAIN OUTCOMES AND MEASURES: Adjusted hazard ratio (aHR) of ACM and PCSM risk. RESULTS: Of 30 461 patients included in the discovery cohort, the median (IQR) age was 64 (59-68) years; of 12 837 patients included in the validation cohort, the median (IQR) age was 59 (54-64) years. Compared with patients with undetectable PSA, among patients with persistent PSA, a pre-RP PSA level greater than 20 ng/mL vs 20 ng/mL or less was significantly associated with reduced ACM risk (aHR, 0.69; 95% CI, 0.51-0.91; P = .01; P for interaction < .001) and PCSM risk (aHR, 0.41; 95% CI, 0.25-0.66; P < .001; P for interaction = .02). This result remained after adjustment for prostate volume and was confirmed in the validation cohort for PCSM risk and may represent a higher proportion of patients with a pre-RP PSA greater than 20 ng/mL vs 20 ng/mL or less who could have reached an undetectable PSA level if additional time for PSA assessment occurred before initiating post-RP therapy for presumed persistent PSA. Notably, there was more frequent and a shorter median time to post-RP RT plus ADT or ADT use in patients with a pre-RP PSA greater than 20 ng/mL (244 of 446 [54.7%] at a median [IQR] of 2.68 [1.51-4.40] months) vs 20 ng/mL or less (338 of 972 [34.8%] at a median [IQR] of 3.30 [2.00-5.39] months). These treatment times were shorter than the times to an undetectable PSA in observed patients (median [IQR] of 2.96 [1.84-3.29] months vs 3.37 [2.35-4.09] months, respectively). Increasing persistent PSA level was associated with an increased ACM risk (aHR, 1.14; 95% CI, 1.04-1.24; P = .004) and PCSM risk (aHR, 1.27; 95% CI, 1.12-1.45; P < .001). CONCLUSIONS AND RELEVANCE: PSA level assessed for at least 3 months after RP may minimize overtreatment, and in this study, a higher persistent PSA level was associated with a worse prognosis.
引用
- Tilki D, Chen MH, Wu J, et al. Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk. JAMA Oncol. 2025. PMID: 40080000. doi:10.1001/jamaoncol.2025.0110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。